SCHEMBL12372559

SCHEMBL12372559

CC(C)(C)N1CCC(n2c(=O)[nH]c3cnccc32)CC1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TNKS O95271 6/20 0.51
TNKS2 Q9H2K2 1/20 0.51
DRD2 P14416 2/20 0.48
KCNH2 Q12809 1/20 0.48
CYP3A4 P08684 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
HSD11B1 P28845 1/20 0.43
OPRM1 P35372 2/20 0.43
OPRK1 P41145 1/20 0.43
OPRL1 P41146 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12372558 0.90 TNKS (0.51) TNKSTNKS2DRD2CYP3A4CHRM2
SCHEMBL6215045 0.85 TNKS (0.60) TNKSTNKS2DRD2KCNH2CYP3A4
SCHEMBL13081097 0.84 DRD2 (0.54) TNKSTNKS2DRD2KCNH2CYP3A4
SCHEMBL16455915 0.84 TNKS (0.54) TNKSTNKS2DRD2KCNH2CYP3A4
SCHEMBL13351356 0.83 TNKS (0.51) TNKSTNKS2DRD2KCNH2CYP3A4
SCHEMBL23952719 0.83 TNKS (0.55) TNKSTNKS2DRD2KCNH2CYP3A4
SCHEMBL12403053 0.82 DRD2 (0.56) TNKSTNKS2DRD2KCNH2CYP3A4
SCHEMBL16455972 0.82 TNKS (0.57) TNKSTNKS2DRD2KCNH2CYP3A4
SCHEMBL16456311 0.82 TNKS (0.57) TNKSTNKS2DRD2KCNH2CYP3A4
SCHEMBL5962492 0.82 CHRM1 (0.64) CHRM2CHRM4CHRM1CHRM3HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994325-B2 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide MERCK SHARP & DOHME CORP. (US) 2011-08-09 US disclosed
US-7947678-B2 Heterocyclic benzodiazepine CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-24 US disclosed
US-7947678-B2 Heterocyclic benzodiazepine CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-24 US disclosed
US-7732438-B2 CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2010-06-08 US disclosed
US-20080261972-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2008-10-23 US disclosed
US-20070287697-A1 Cgrp Receptor Antagonists MERCK SHARP & DOHME LLC 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261972-A1 Cgrp Receptor Antagonists BDKRB1, CALCRL, NPY1R TNKS 3019/4885TNKS2 3196/4885DRD2 805/4885
US-20070287697-A1 Cgrp Receptor Antagonists BDKRB1, BDKRB2, CCKBR TNKS 3347/4885TNKS2 3075/4885DRD2 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.